Pompe Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pompe Disease stocks.

Pompe Disease Stocks Recent News

Date Stock Title
Nov 20 SNY CDC warns of an imminent spike in COVID, flu cases
Nov 20 SNY Here’s What Drove Sanofi’s (SNY) Earnings
Nov 20 SNY Sanofi: Information concerning the total number of voting rights and shares - October 2024
Nov 19 BMRN BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now
Nov 19 FOLD HALO vs. FOLD: Which Stock Should Value Investors Buy Now?
Nov 18 SNY FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Nov 16 BMRN BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
Nov 15 SNY How analysts are reacting to RFK Jr. as Trump's HHS pick
Nov 15 SNY FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
Nov 15 SNY Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
Nov 15 SNY Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk
Nov 15 SNY Trump’s RFK Jr. Pick Weighs on Vaccine Makers
Nov 15 SNY Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
Nov 15 SNY European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
Nov 15 SNY EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
Nov 15 SNY Drugmaker stocks slide as Trump picks vaccine sceptic RFK Jr for US health job
Nov 15 SNY Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Nov 15 SNY Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Nov 15 SNY Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Nov 14 SNY Vaccine makers close lower amid reports RFK Jr may head HHS (update)
Pompe Disease

Glycogen storage disease type II, also called Pompe disease, is an autosomal recessive metabolic disorder which damages muscle and nerve cells throughout the body. It is caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. It is the only glycogen storage disease with a defect in lysosomal metabolism, and the first glycogen storage disease to be identified, in 1932 by the Dutch pathologist J. C. Pompe.
The build-up of glycogen causes progressive muscle weakness (myopathy) throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver and the nervous system.

Browse All Tags